Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Acetylcholinesterase Inhibitor
Dehydrogeijerin is a potent inhibitor of acetylcholinesterase, exhibiting an IC50 value of 9.7 μM. This compound is particularly relevant for research into Alzheimer’s disease, where the modulation of acetylcholine levels can influence disease pathology. Dehydrogeijerin's ability to inhibit acetylcholinesterase makes it a valuable tool for exploring therapeutic strategies aimed at enhancing cholinergic signaling in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-86 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 25.33 μg/mL. This compound effectively inhibits AChE by forming hydrogen bonds and π-π and π-alkyl interactions with critical amino acid residues at the enzyme's catalytic sites. AChE-IN-86 is applicable in research focused on Alzheimer's disease, making it a valuable tool for studying cholinergic dysfunction associated with neurodegeneration. -
Acetylcholinesterase Inhibitor
Paecilomide is a pyridone alkaloid that acts as an acetylcholinesterase inhibitor. This compound exhibits key biological activity by enhancing cholinergic signaling, making it significant for research applications related to neurodegenerative diseases such as Alzheimer's. Its ability to inhibit acetylcholinesterase enables the study of cholinergic neurotransmission and potential therapeutic interventions. -
AChE Inhibitor
AChE-IN-25 is a potent and selective uncompetitive inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.95 µM. This compound demonstrates significant potential for modulating cholinergic activity, making it a valuable tool in Alzheimer's disease research and related neurodegenerative studies. Its ability to effectively inhibit AChE can aid in understanding and investigating therapeutic strategies targeting cholinergic deficiencies. -
Acetylcholinesterase inhibitor
AChE-IN-37 is an acetylcholinesterase inhibitor featuring an IC50 value of 0.23 μM. This compound modulates reactive oxygen species (ROS) levels and influences the gene expression of NRF2. AChE-IN-37 is applicable in research focused on neurodegenerative diseases and oxidative stress-related studies. -
BChE Inhibitor
Z164597606 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 1.3 μM and 1.7 μM for equine and human BChE, respectively. The compound interacts with the enzyme through π-π stacking with the Trp82 residue, facilitating its inhibitory effect. Z164597606 is applicable in research focused on Alzheimer’s disease, enabling investigations into therapeutic strategies targeting cholinesterase activity. -
AChE Inhibitor
AChE-IN-91 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 0.05 μM. It exhibits significant anticholinesterase activity, making it a valuable tool for research into neurological disorders, particularly Alzheimer's disease. This compound facilitates the study of cholinergic signaling and potential therapeutic strategies in neurodegeneration. -
AChE Inhibitor
Isocorydine N-oxide is an alkaloid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant activity that may contribute to the modulation of neurotransmitter levels, making it a valuable tool in research focused on neurodegenerative diseases such as Alzheimer's disease. It is utilized to explore therapeutic strategies aimed at enhancing cholinergic function and improving cognitive outcomes in affected individuals. -
BChE Inhibitor
BChE-IN-20 is a potent and selective inhibitor of butyrylcholinesterase (BChE), demonstrating IC50 values of 105 nM for equine BChE and 2.3 nM for human BChE. Additionally, it inhibits P-glycoprotein with an IC50 of 0.27 μM. This compound serves as a valuable template for the design and development of BChE-selective ligands relevant to pharmacological research, including inhibitors and fluorogenic probes. -
BChE Inhibitor
Blestrin D is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 8.1 μM. Isolated from Bletilla striata, this compound is valuable for investigating the biochemical pathways involved in Alzheimer's disease (AD). Its ability to inhibit BChE makes it an important tool for studying cholinergic dysfunction associated with neurodegenerative conditions. -
AChE Inhibitor
AChE-IN-22 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.88 μM and 10 μM, respectively. This compound interacts with both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, making it a valuable tool for studies related to Alzheimer's disease. AChE-IN-22 is suitable for research applications focused on cholinergic system modulation and neurodegenerative disease mechanisms. -
Cholinesterase (ChE) Inhibitor
eeAChE-IN-2 is a highly potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2 nM. This compound serves as a valuable tool for studying cholinergic signaling and its modulation in various biological systems. Its application extends to research on neurodegenerative disorders and cognitive function, where AChE inhibition plays a critical role. -
AChE/BChE Inhibitor
AChE/BChE-IN-5 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. This compound is capable of crossing the blood-brain barrier (BBB), making it significant for research in neurodegenerative diseases and cognitive disorders. It serves as a valuable tool for studying the modulation of cholinergic signaling and the potential therapeutic effects in conditions such as Alzheimer's disease. -
AChE Inhibitor
Isonaringin is an acetylcholinesterase (AChE) inhibitor that demonstrates potential anti-Alzheimer's activity. By inhibiting AChE, Isonaringin increases acetylcholine levels in the brain, which may help improve cognitive function in neurodegenerative conditions. This compound is relevant for research applications focused on Alzheimer's disease and other related disorders. -
AChE Inhibitor
Zifrosilone is an orally active acetylcholinesterase (AChE) inhibitor, exhibiting a mean maximum inhibition of 20.9% at a dosage of 10 mg. This compound is useful in the study of neurological disorders, providing a valuable tool for research into conditions related to cholinergic dysfunction. Its selective targeting of AChE makes it an important reagent for investigating therapeutic strategies in neurodegenerative diseases. -
AChE Inhibitor
Ambenonium dichloride tetrahydrate is a potent, orally active, reversible inhibitor of acetylcholinesterase (AChE). This compound demonstrates a high affinity for human AChE, with an IC50 value of 0.7 nM, making it valuable for investigations into cholinergic system modulation. Its primary applications include the study of neurodegenerative diseases such as myasthenia gravis and Alzheimer's disease, as well as broader neuropharmacological research. -
BuChE Inhibitor
BuChE-IN-1 is a potent inhibitor of butyrylcholinesterase (BuChE), a key enzyme implicated as a biomarker in the progression of Alzheimer’s disease (AD). This compound exhibits low cytotoxicity and demonstrates excellent permeability across the blood-brain barrier (BBB). BuChE-IN-1 is an advantageous tool for investigating the role of BuChE in AD research and exploring therapeutic interventions. -
AChE Inhibitor
K027 is a potent reactivator of acetylcholinesterase (AChE) inhibited by organophosphates (OP). It effectively restores AChE activity, making it valuable for studying neurodegenerative conditions such as Alzheimer's disease. K027's mechanism and specificity provide a useful tool for investigating therapeutic strategies targeting cholinergic dysfunction. -
Cholinesterase (ChE) Inhibitor
hAChE-IN-4 is a potent inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 0.25 μM, demonstrating effective permeability across the blood-brain barrier. This compound plays a significant role in research related to Alzheimer's disease, where modulation of cholinergic activity is critical. Its use can aid in exploring therapeutic strategies targeting cholinesterase activity in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-26 is an acetylcholinesterase (AChE) inhibitor with a reported IC50 of 0.42 μM. This compound plays a significant role in research related to Alzheimer's disease by inhibiting the breakdown of acetylcholine, thereby enhancing cholinergic transmission. AChE-IN-26 serves as a valuable tool for studying pathophysiological mechanisms associated with neurodegeneration and for evaluating potential therapeutic strategies. -
Cholinesterase Inhibitor
Magnotriol B is a potent cholinesterase inhibitor, demonstrating IC50 values of 12.63 nM against acetylcholinesterase (AChE) and 14.5 nM against butyrylcholinesterase (BChE). Additionally, it exhibits notable nitric oxide (NO) inhibitory activity, with an IC50 of 2.02 μM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, offering potential insights into therapeutic strategies targeting cholinergic dysfunction. -
AChE Inhibitor
Chikusetsusaponin Ib is a potent inhibitor of acetylcholinesterase (AChE), a key enzyme involved in neurotransmission. This compound exhibits significant anti-Alzheimer's disease activity, making it a valuable tool for research focused on neurodegenerative disorders. Its ability to modulate AChE activity can aid in the exploration of therapeutic strategies aimed at enhancing cognitive function and addressing Alzheimer’s pathology. -
AChE Inhibitor
Picfeltarraegenin X is a triterpenoid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits notable biological activity by enhancing acetylcholine levels, making it relevant for studies focused on neurodegenerative disorders such as Alzheimer's disease. Picfeltarraegenin X is useful in research applications aimed at understanding cholinergic signaling and developing potential therapeutic strategies targeting cognitive decline. -
Cholinesterase (ChE) Inhibitor
Cyclopenin is a cholinesterase (ChE) inhibitor that effectively modulates acetylcholine levels by preventing its breakdown. This compound exhibits significant biological activity in the study of neurodegenerative diseases and offers potential applications in the examination of cognitive disorders. Researchers can leverage Cyclopenin’s properties for investigations into synaptic transmission and cholinergic signaling pathways. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
Acetylcholinesterase Inhibitor
ω-Hydroxydigitoemodin is an anthraquinone derivative that functions as an acetylcholinesterase inhibitor. This compound exhibits significant anti-acetylcholinesterase activity and has been identified in the marine fungus Trichoderma harzianum XS-20090075. It is utilized in research exploring neurodegenerative diseases and potential therapeutic approaches targeting cholinergic signaling pathways. -
AChE/BChE Inhibitor
AChE/BChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 6.08 μM and 0.383 μM against electric eel AChE and equine serum BChE, respectively. This compound demonstrates effective inhibition of cholinesterases, which are important targets in studies related to neurodegenerative diseases and pesticide exposure. AChE/BChE-IN-3 is valuable for research applications focused on understanding cholinergic signaling and developing therapeutic strategies for conditions such as Alzheimer's disease. -
AChE Inhibitor
AChE-IN-30 is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 4.4 μM. It exhibits neuroprotective properties by inhibiting H2O2-induced apoptosis through the reduction of intracellular reactive oxygen species (ROS) accumulation. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
BChE Inhibitor
Bisnorcymserine is a potent inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.228 nM. This compound effectively reduces levels of amyloid-β peptide (Aβ) and has demonstrated therapeutic potential in ameliorating symptoms of Alzheimer's Disease in aged rat models. Bisnorcymserine's ability to penetrate the blood-brain barrier makes it a valuable tool for research in neurodegenerative disorders. -
BChE Inhibitor
BChE-IN-12 is a non-competitive inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 2.3 μM. Isolated from Bletilla striata, this compound demonstrates significant inhibitory activity that can aid in the investigation of cholinergic dysfunction. BChE-IN-12 is particularly relevant for research applications focused on Alzheimer's disease and other cognitive disorders where BChE modulation may play a therapeutic role. -
AChE/BChE Inhibitor
AChE/BChE-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 792 nM for human AChE and 2.2 nM for human BChE. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's. Its selective inhibition profile provides insights into cholinergic system modulation and potential therapeutic applications. -
NTE Inhibitor
KBR 2822 is a selective inhibitor of neurological target esterase (NTE) and exhibits inhibitory activity against acetylcholinesterase (AChE). This compound is utilized in research to investigate the mechanisms of neurological damage and the role of NTE in neurotoxicity. While KBR 2822 can exacerbate neurological damage under specific conditions, it does not induce neurological disease when administered alone without direct neurotoxic effects or biochemical alteration. -
AChE Inhibitor
AChE-IN-8 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 1.95 μM. It is primarily utilized in research focused on Alzheimer's disease, where inhibition of AChE can aid in the enhancement of acetylcholine levels in the synaptic cleft. This compound serves as a valuable tool for investigations into therapeutic strategies for cognitive decline associated with neurodegenerative disorders. -
AChE Inhibitor
ACHE-IN-38 hydrochloride is a potent acetylcholinesterase (AChE) inhibitor that effectively reduces the breakdown of the neurotransmitter acetylcholine. By enhancing cholinergic transmission, this compound shows promise in alleviating memory deficits associated with Alzheimer's Disease. It serves as a valuable tool for research into neurodegenerative disorders and the pharmacological modulation of cognitive functions. -
BuChE Inhibitor
BuChE-IN-12 is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.52 µM, targeting the catalytic and peripheral anionic sites. This compound has demonstrated potential against oxidative stress, making it valuable for exploring therapeutic approaches in Alzheimer's disease research. BuChE-IN-12 serves as a useful tool for investigating the role of BuChE in neurotransmission and related neurodegenerative conditions. -
BChE Inhibitor
S21-1011 is a selective inhibitor of butyrylcholinesterase (BChE) with IC50 values of 0.059 μM for equine BChE and 0.162 μM for human BChE. This compound demonstrates effective blood-brain barrier permeability and favorable pharmacokinetic properties. Additionally, S21-1011 exhibits anti-inflammatory activity by activating the keap1-Nrf2-ARE signaling pathway, with an EC50 of 23.48 μM for antioxidant response element activation. Its potential to ameliorate cognitive impairments in murine models of Alzheimer’s disease makes it relevant for neurodegenerative research applications. -
AChE Inhibitor
AChE-IN-17 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 28.98 μM. This compound demonstrates significant neuroprotective effects by preventing hydrogen peroxide-induced cell death in PC12 cells. AChE-IN-17 is valuable for research focused on neurodegenerative diseases, providing insights into therapeutic strategies for conditions characterized by cholinergic dysfunction. -
AChE Inhibitor
AChE-IN-6 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting significant inhibitory activity against both eel AChE (IC50 = 0.20 μM) and human AChE (IC50 = 37.02 nM). Additionally, AChE-IN-6 demonstrates robust anti-amyloid beta activity, with IC50 values of 1.92 μM for inhibiting self-induced Aβ1-42 aggregation and 1.80 μM for promoting disaggregation of Aβ1-42 fibrils. These properties suggest its utility in Alzheimer's disease research, particularly in exploring therapeutic strategies targeting cholinergic dysfunction and amyloid pathology. -
Cholinesterase Inhibitor
BChE-IN-45 is a competitive cholinesterase inhibitor designed to target butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). It demonstrates an inhibition constant (Ki) of 11.13 μM for dual action, with IC50 values of 13.8 μM for BChE and 35.63 μM for AChE. BChE-IN-45 is a valuable tool for research focused on neurodegenerative conditions, particularly Alzheimer's disease, enabling the exploration of cholinergic system modulation. -
AChE/BChE Inhibitor
AChE/BChE-IN-11 is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 70 μM and 71 μM, respectively. This natural product, derived from artichoke leaves, exhibits significant biological activity relevant to neurodegenerative disorders. AChE/BChE-IN-11 can be utilized in studies investigating Alzheimer's disease and other conditions linked to cholinergic dysfunction, facilitating the exploration of therapeutic options targeting cholinesterase enzymes. -
AChE/BuChE Inhibitor
AChE/BuChE-IN-1 is a selective butyrylcholinesterase (BuChE) inhibitor that exhibits an IC50 of 0.48 μM for BuChE and 7.16 μM for acetylcholinesterase (AChE). This compound demonstrates significant scavenging activity against reactive oxygen species (·OH) with an IC50 of 0.1674 μM and effectively inhibits Aβ1-42 aggregation under various conditions (self-, Cu2+-induced, AChE-induced). With high blood-brain barrier permeability and bioavailability, alongside low cytotoxicity, AChE/BuChE-IN-1 is valuable for research into Alzheimer’s disease pathophysiology and therapeutic strategies. -
AChE Inhibitor
Acotiamide hydrochloride is a selective and reversible inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 1.79 μM. This compound is known to enhance gastric contractility and promote accelerated gastric emptying. Acotiamide hydrochloride is primarily utilized in research focused on functional dyspepsia related to gastric motility dysfunction and intestinal inflammation. -
Acetylcholinesterase Inhibitor
Eseramine is a weak acetylcholinesterase inhibitor with an IC50 value of 9300 nM. Its primary mechanism involves the modulation of acetylcholinesterase activity, making it relevant for research into conditions such as glaucoma, myasthenia gravis, and organophosphate poisoning-related protection. Eseramine serves as a valuable tool in the exploration of therapeutic strategies targeting acetylcholinesterase regulation in various neurological disorders. -
AChE Inhibitor
AChE-IN-92 is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. By inhibiting AChE activity, it effectively prevents the hydrolysis of acetylcholine, leading to increased synaptic levels of this neurotransmitter. AChE-IN-92 is a valuable tool for research focusing on Alzheimer’s disease and related neurodegenerative disorders. -
Acetylcholinesterase Inhibitor
AChE-IN-113 is a selective inhibitor of acetylcholinesterase, exhibiting a Ki value of 8.3 μM against electric eel acetylcholinesterase. This compound is utilized in research focused on Alzheimer's disease, allowing for the investigation of cholinergic signaling pathways and the potential therapeutic implications in neurodegeneration. Its specificity for acetylcholinesterase makes it a valuable tool for studying enzyme activity and related disorders. -
Cholinesterase (ChE) Inhibitor
Picfeltarraenin IV is a triterpenoid compound that acts as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant potential for modulating cholinergic neurotransmission, making it relevant for studies related to neurological conditions. Additionally, Picfeltarraenin IV demonstrates biological activities that may be beneficial in the treatment of herpes infections, cancer, and inflammatory disorders. Its diverse therapeutic applications make it a valuable reagent for research in pharmacology and medicinal chemistry. -
AChE Inhibitor
Chondrocurine, an alkaloid derived from the roots of Cissampelos pareira Linn., functions as an acetylcholinesterase (AChE) inhibitor with an IC50 of 7.46 μM. This compound demonstrates significant activity in modulating cholinergic signaling, making it a valuable tool for studying neuropharmacology and related fields. Its application in research may extend to investigations of neurodegenerative diseases and neuromuscular junction disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE Inhibitor
2-Hydroxyalbrassitriol is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 of 35.97 μM. This compound is utilized in research focused on neurodegenerative diseases and cognitive function by modulating cholinergic signaling. Its inhibition of AChE makes it a valuable reagent for studies investigating potential therapeutic strategies for conditions such as Alzheimer's disease. -
BChE Inhibitor
BChE-IN-5 is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 of 2.8 nM, demonstrating greater potency against human BChE compared to human acetylcholinesterase (hAChE). This compound is valuable for research focused on neurodegenerative disorders, particularly Alzheimer's disease, by modulating cholinergic signaling pathways. Its specificity and efficacy make BChE-IN-5 a significant tool in elucidating the role of BChE in cognitive decline and related pathologies.
